Clinical Trial Update: Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating N-acetylcysteine for cognitive and negative symptoms in schizophrenia has completed recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Deficits
• Schizophrenia

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Schizophrenia, Cognitive Deficits | Phase 4 | Status: COMPLETED